Caricamento...
The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX(®) Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX...
Salvato in:
| Pubblicato in: | Front Pharmacol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6546897/ https://ncbi.nlm.nih.gov/pubmed/31191299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00524 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|